| Literature DB >> 23916506 |
Hengameh Firouzmand1, Ali Badiee, Ali Khamesipour, Vahid Heravi Shargh, Seyedeh Hoda Alavizadeh, Azam Abbasi, Mahmoud Reza Jaafari.
Abstract
A suitable adjuvant and delivery system are needed to develop an effective vaccine against leishmaniasis. To induce a Th1 type of response and protection in BALB/c mice against Leishmania major infection, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) nanoliposomes bearing an intrinsic adjuvanticity, were used as an antigen delivery system and immunoadjuvant for soluble Leishmania antigens (SLA). DOTAP liposomes containing different concentrations of SLA were prepared by using lipid film method followed by sonication. The prepared vesicles showed a diameter of about 100nm, a positive zeta potential and approximately 70% encapsulation efficiency of SLA. BALB/c mice were immunized subcutaneously (SC), three times in a 3-week interval with different concentrations of liposomal SLA (12.5, 25, and 50μg of SLA/50μl/mice), free SLA and as well as free liposome. The group of mice received 50μg of SLA in DOTAP-nanoliposomes showed a significantly (p<0.001) smaller footpad swelling and the lowest spleen and footpad parasite burden after the challenge. This group also showed the highest IFN-γ production compared to the other groups, lower IL-4 level and higher IgG2a antibody titer. Taken together, the results indicated that simple DOTAP nanoliposome containing 1μg/μl SLA are appropriate delivery systems to induce a Th1 type of immune response and protection against L. major infection in BALB/c mice.Entities:
Keywords: Adjuvant; DOTAP; Leishmaniasis; Nanoliposomes; SLA; Vaccine
Mesh:
Substances:
Year: 2013 PMID: 23916506 DOI: 10.1016/j.actatropica.2013.07.021
Source DB: PubMed Journal: Acta Trop ISSN: 0001-706X Impact factor: 3.112